Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
about
Development of Human Membrane Transporters: Drug Disposition and PharmacogeneticsPharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapyThe organic anion transporter (OAT) family: a systems biology perspectiveAssociation of ABCC2 -24C>T polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemiaPharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemiaThe Promise of Pharmacogenomics in Reducing Toxicity During Acute Lymphoblastic Leukemia Maintenance Treatment.Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance.Inherited genetic variation in childhood acute lymphoblastic leukemia.Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters.What do drug transporters really do?Pharmacogenetics of childhood acute lymphoblastic leukemia.New insights in the biology of ABC transporters ABCC2 and ABCC3: impact on drug disposition.Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.Advances and challenges in hereditary cancer pharmacogenetics.MTHFR polymorphisms in childhood acute lymphoblastic leukemia: influence on methotrexate therapy.Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.Vincristine pharmacokinetics pathway and neurotoxicity during early phases of treatment in pediatric acute lymphoblastic leukemia.Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.SLC19A1 hot spot for MTX plasma concentration.Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.Upregulated solute carrier family 37 member 1 in colorectal cancer is associated with poor patient outcome and metastasis.Association between SLC19A1 Gene Polymorphism and High Dose Methotrexate Toxicity in Childhood Acute Lymphoblastic Leukaemia and Non Hodgkin Malignant Lymphoma: Introducing a Haplotype based Approach.Possible roles of genetic variations in chemotherapy related cardiotoxicity in pediatric acute lymphoblastic leukemia and osteosarcoma.
P2860
Q26786582-4E51F74D-1644-423B-80CF-84ACB95F30A4Q28083449-D44FF4B3-68A2-44B4-B3D9-59AF9B054D76Q28085671-9F964438-5373-4BBD-9A44-9C836FF9C4B3Q28538292-4EDF67E7-A4A5-45DB-A7AF-4DCF54042BADQ28540685-44D11E15-41BC-4019-AA12-7375B35093D8Q33632120-A2152DE1-7312-47F6-962F-92CA7217827EQ33914131-35B46D27-E8A6-41DB-A748-A0F732F31F25Q34065294-ACCDADDA-6B57-4AD6-9C1F-AF6136D6A3C3Q35784497-ED0C7E65-117B-4FB0-B64F-7CB843FD11EEQ36250282-8E0B443C-03C6-4B6A-84A8-48864B7C19A8Q36571217-3DDDAB56-1D57-4F83-9A66-E1A3551D2E09Q38243175-9B57B6E5-37A6-46CA-AC17-56F095EE0162Q38266172-9DFF7527-D548-4911-B29C-676B54EFC50BQ38506522-0322B012-6872-48F7-A72A-825BE72B060FQ38888350-F79DB283-ED92-4170-B1A3-130494507485Q38888369-8945AC72-5322-422E-85D9-44342BB4F399Q38895172-C6644E3D-2DE8-4A5E-9E04-9240487523AEQ38948499-CA968E10-FBA3-4DE5-8F8B-6E58CE965671Q39230513-5C190E93-5499-491A-935D-5EAAE3D5A61FQ42706096-514455A2-F386-4532-9FFD-3C7E1189889FQ47310338-92A12EAC-3A92-4627-BF23-9F7C7A7CBE7EQ47592832-A3B827AA-5286-45B8-93CB-2286C78F2DA7Q47608710-04C4F9FF-A257-4C72-8D95-B3B33D1F5728Q48331843-B3ABDC6D-8B90-4FC1-91F5-3851212A264BQ49486006-23004331-2DA6-47E1-B336-E29FF0197725Q49703642-4C2B1603-0D64-4EA0-B4F1-9C84C9EA9441Q55518023-C78DF030-D85E-451E-816D-4B333BC53288
P2860
Polymorphisms in the methotrexate transport pathway: a new tool for MTX plasma level prediction in pediatric acute lymphoblastic leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@en
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@nl
type
label
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@en
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@nl
prefLabel
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@en
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@nl
P2093
P1476
Polymorphisms in the methotrex ...... acute lymphoblastic leukemia.
@en
P2093
Africa Garcia-Orad
Aurora Navajas
Elixabet Lopez-Lopez
Javier Ballesteros
José Sanchez de Toledo
Maria A Piñan
Nagore Garcia de Andoin
Purificacion Garcia-Miguel
P356
10.1097/FPC.0B013E32835C3B24
P577
2013-02-01T00:00:00Z